Description
MEDICATION COATED BALLOON
For the treatment of femoropopliteal disease in which 75% of patients do not require re-intervention at 5 years. This is more important now than ever.†
NOW SUPPORTED BY 5-YEAR AND GLOBAL WORKING DATA
For treatment of femoropopliteal disease with 75% of patients reintervention-free at 5 years.1 This matters now more than ever.†
Maintain long-term patency with the IN.PACT Admiral drug-coated balloon (DCB); this provides durable, consistent and safe results across multiple clinical trials as well as complex patient and lesion types. With more than 3,500 patients enrolled in 21 clinical trials and more than 500,000 patients treated worldwide, the IN.PACT Admiral balloon is the market-leading DCB for the treatment of femoropopliteal disease.
IN.PACT Admiral DCB is a clinically proven primary endovascular therapy that treats femoropopliteal disease, reducing interventions and preserving future treatment options.
DURATION OF PACLITAXEL IN TISSUE
Only IN.PACT Admiral DCB releases drug into tissue through the restenotic window.
| Feature | Features |
|---|---|
| Paclitaxel Drug Dosage | 3.5 µg/mm 2 |
| Excipient | Urea |
| Balloon Diameters | 4.0 to 7.0 mm |
| Balloon Sizes | 40, 60, 80, 120, 150, 200, and 250 mm ll |
| Balloon Fold Configurations | 4.0 mm: 3 folds; 5.0, 6.0, and 7.0 mm: 6 folds |
| Catheter Design | Over-the-wire (OTW) |
| Catheter Lengths | 80 and 130 cm |
| Guidewire Compatibility | 0.035 in |
